Background "Patient-Reported Outcome" (PRO) is used as an umbrella term for different concepts for measuring subjectively perceived health status e. g. 
period from 1990 to 2009, the search for clinical trials of rheumatoid arthritis and breast cancer covers the period 2005 to 2009. Both searches were performed in the medical databases of the German Institute of Medical Documentation and Information (DIMDI). The search for HTA-reports and methodological papers of HTA-agencies was performed in the CRD-Databases (CRD = Centre for Reviews and Dissemination) and by handsearching the websites of INAHTA member agencies (INAHTA = International Network of Agencies for Health Technology Assessment). For all issues specific inclusion and exclusion criteria were defined. The methodological quality of randomized controlled trials (RCT) was assessed by a modified version of the Cochrane Risk of Bias Tool. For the methodological part information extraction from the literature is structured by the report's chapters, for the empirical part data extraction sheets were constructed. All information is summarized in a qualitative manner.
Results
Concerning the methodological issues the literature search retrieved 158 documents (87 documents related to definition or classification, 125 documents related to operationalisation of PRO). For the empirical analyses 225 RCT (rheumatoid arthritis: 77; breast cancer: 148) and 40 HTA-reports and method papers were found. The analysis of the methodological literature confirms the role of PRO as an umbrella term for a variety of different concepts. The newest classification system facilitates the description of PRO measures by construct, target population and the method of measurement. Steps of operationalisation involve defining a conceptual framework, instrument development, exploration of measurement properties or, possibly, the modification of existing instruments. Seven out of 59 RCT analysing the effects of antibody therapy for rheumatoid arthritis define PRO as the primary endpoint, 38 trials utilize composite measures (ACR, DAS) and ten trials report clinical or radiological parameters as the primary endpoint. Six out of 123 chemotherapy
Summary Health political background
In Germany the legal framework of the SGB V puts the evaluation of the "medical benefit" in the centre of a technology assessment, although the term "benefit" is not defined by legislation. However, the wording of § 27 suggests, that the requirements of SGB V can be fulfilled by reporting a technology's effects on morbidity, mortality and quality of life. Further characterisations of these endpoints are found in the "Methodenpapier 3.0 (05/27/2008)" of the Institute for Quality and Efficiency in Health Care (IQWiG). In chapter 3.1. the expression "patient-relevant" is defined as "… how a patient feels, is able to function and participate or survive." Aside from morbidity, mortality and quality of life, intervention-or disease-specific efforts and patients' satisfaction with treatment may constitute secondary endpoints. It is mandatory, that all kinds of endpoints directly and reliably indicate changes in health status. Finally, the only way to validly assess patients' quality of life, some aspects of morbidity and patient satisfaction is by direct questioning of the patients -that is why they are called PatientReported Outcomes (PRO).
Scientific background
PRO is used as an umbrella term for different concepts aiming at the measurement of subjectively perceived health status e. g. as treatment effects. Their common characteristic is, that the appraisal of the health status is reported by the patient himself. The American Food and Drug Administration (FDA) defines PRO as follows: "A PRO is any report of the status of a patient's health condition that comes directly from the patient, without interpretation of the patient's response by a clinician or anyone else". PRO are used if a concept may be assessed best by the patient himself. PRO may be elicited either as a single value (e. g. severity of pain) or as a value of change between two measurements (e. g. pain cessation). The measurement of PRO is based on two different approaches. The psychometrical approach refers to the reporting of perceived symptoms (e. g. their presence and severity), capabilities, behaviours, or emotional or mental state. Single dimensions may be summarised forming complex concepts (e. g. quality of life). The preferencebased approach refers to the value a patient assigns to a specific health status. Methodological approaches to elicit preferences are based on econometrics and decision theory. The following text exclusively refers to the psychometrical approach. Aside from health economics, there are two main applications for PRO measurements: as indicators for quality management in health care and as an endpoint in clinical trials. Assessing the benefit of a health care technology on the basis of published clinical trials is the main goal of Health Technology Assessment (HTA). Therefore, determining the role of PRO in HTA will focus on their application in clinical trials. Psychometric properties such as sufficient validity (content, construct, and criterion), reliability and responsiveness are basic requirements for instruments measuring PRO in clinical trials. Other aspects are administrative and economic feasibility and acceptability. In order to outline the informative value of PRO in HTA, first of all an overview of concepts, classifications and methods of measurement for PRO is needed. Strengths and weaknesses of the different concepts and measurement approaches need to be pointed out, especially with regard to their psychometric properties and interpretability of results. The overview is based on a systematic analysis of publications that deal with the theoretical framework for the evaluation of PRO. The current role of PRO measurements in HTA is outlined by two empirical analyses. The first one determines the frequency, the type and consequences of PRO measurement in randomized controlled trials (RCT). Treatment of rheumatoid arthritis with biologicals and chemotherapy of breast cancer were chosen as examples. These indications -treatment pairs were selected in order to represent one chronic disease and one life-threatening acute disease. The second empirical analysis focuses on the role of PRO in the work of HTA-agencies. HTA-reports on the two example conditions are analysed to determine to which extent conclusions of the reports are based on PRO. Furthermore, method guides of international HTA-agencies are screened in order to determine the role that these agencies attribute to PRO measurements. These overarching objectives are broken down into eight research questions. During the development of new instruments item generation is a pivotal step. According to the literature a mixed approach consisting of literature studies, expert input and focus groups is considered state of the art. Measurement properties are crucial for the applicability of an instrument. Main properties are validity, reliability and responsiveness. Validity may be determined as content, construct or criterion validity -depending on the type of instrument and the available comparisons. Reliability primarily refers to test-retest-reliability and internal consistency. Responsiveness describes the ability of an instrument to record changes of an endpoint. It is determined by a distribution based or an anchor based approach. The former utilizes effect size while the latter requires comparisons with an external anchor (gold standard).
Research questions
A pivotal concept for the interpretation of results from PRO measurements is the minimal important difference (MID) -describing the smallest difference between two measurement results that a patient considers relevant. There is no standard approach to determine the MID. The most frequently used approaches correspond with the approaches used to determine responsiveness. For methodological and economical reasons the use of existing standardised and validated instruments is preferable to the development of new instruments. In some situations it may be necessary to modify an instrument to match a specific context. A particularly critical point is the translation of instruments into a foreign language. Guidelines suggest a ten-step process of forward and backward translations. In any case a modified instrument needs to be revalidated.
PRO in clinical trials
The literature searches retrieved 73 publications reporting on 59 RCT that investigate the effects of treating rheumatoid arthritis with biological drugs. Most frequently the American College of Rheumatology (ACR) core set of disease activity measures is used as the primary endpoint. This composite endpoint consists of seven criteria, among them three PRO (pain, global assessments of health status and functioning). For a positive score, improvements in at least one PRO criterion are required. The 20-percent criterion, which requires an overall 20-percent improvement is used as primary endpoint in 23 studies. Pure PRO are less frequently used as primary endpoints. The most frequently applied PRO is the health assessment questionnaire (HAQ), a questionnaire investigating functional status by 20 items. It is defined as the primary endpoint in six trials. The disease activity score (DAS) is the most frequently studied secondary endpoint (39 trials). The DAS again is a composite endpoint consisting of four criteria, among them one PRO (health perception 
PRO in HTA-reports (rheumatoid arthritis)
Handsearches and database searches identified nine HTA-reports addressing the treatment of rheumatoid arthritis with biological drugs. In their background section seven reports justified the use of PRO for this indication by referring to the disease's impact on functional status and quality of life. Analyses of the methods section of reports revealed that nearly half of the documents prospectively specified PRO as relevant endpoints for the assessment. Predominantly the composite endpoints ACR20, ACR50 and ACR70 are referred to but single measures of symptoms (pain scale), functioning (HAQ) or quality of life are mentioned as well. In all reports results of PRO measurements are discussed explicitly, with a special focus on the ACR criteria. Two reports compare the results from traditional endpoints with PRO results. In the majority of reports the results from PRO measurements are regarded insufficient yet for decision making. The authors point out the need for more research in order to bridge the gap.
PRO in HTA-reports (breast cancer)
Twelve HTA-reports were found that assess different types of chemotherapy for breast cancer. In their background section only three of these twelve reports refer to aspects of everyday life that may be impacted by chemotherapy. These reports regard symptom relief and quality of life along with prolongation of life as the main goals of chemotherapy.
As specified in the methods sections, quality of life data and other constructs such as pain, fear, depression and functional status are taken into consideration by five reports. One report refers to PRO for input into cost-utilityanalyses. PRO results, mainly quality of life data, are presented in the results section of four reports. In their discussion section, three reports refer to quality of life data. Of these, two reports discuss the fact that improvements in disease-free survival not necessarily translate into improvements of quality of life. On the other hand the inevitable relation of toxicity and reduced quality of life is pointed out.
Discussion
The results of the presented report may be compromised by some methodological limitations. 
